ABIN188539
antibody from antibodies-online
Targeting: FOXP3
AIID, DIETER, IPEX, JM2, PIDX, SCURFIN, XPID
Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [4]
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN188539 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Forkhead Box P3 (FOXP3) antibody
- Antibody type
- Polyclonal
- Description
- Epitope affinity purified
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Vial size
- 0.1 mL
- Storage
- Aliquot and store at -20°C or -80°C. Avoid freeze-thaw cycles.
- Handling
- Avoid freeze-thaw cycles
Submitted references Competing endogenous RNA network analysis of CD274, IL‑10 and FOXP3 co‑expression in laryngeal squamous cell carcinoma.
Anaphylatoxins Activate Ca2+, Akt/PI3-Kinase, and FOXO1/FoxP3 in the Retinal Pigment Epithelium.
TLR9 activation suppresses inflammation in response to Helicobacter pylori infection.
Inhibition of cyclooxygenase-2 in hematopoietic cells results in salt-sensitive hypertension.
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
Sun J, Lian M, Ma H, Wang R, Ma Z, Wang H, Zhai J, Meng L, Feng L, Bai Y, Cui X, Fang J
Molecular medicine reports 2018 Mar;17(3):3859-3869
Molecular medicine reports 2018 Mar;17(3):3859-3869
Anaphylatoxins Activate Ca2+, Akt/PI3-Kinase, and FOXO1/FoxP3 in the Retinal Pigment Epithelium.
Busch C, Annamalai B, Abdusalamova K, Reichhart N, Huber C, Lin Y, Jo EAH, Zipfel PF, Skerka C, Wildner G, Diedrichs-Möhring M, Rohrer B, Strauß O
Frontiers in immunology 2017;8:703
Frontiers in immunology 2017;8:703
TLR9 activation suppresses inflammation in response to Helicobacter pylori infection.
Varga MG, Piazuelo MB, Romero-Gallo J, Delgado AG, Suarez G, Whitaker ME, Krishna US, Patel RV, Skaar EP, Wilson KT, Algood HM, Peek RM Jr
American journal of physiology. Gastrointestinal and liver physiology 2016 Nov 1;311(5):G852-G858
American journal of physiology. Gastrointestinal and liver physiology 2016 Nov 1;311(5):G852-G858
Inhibition of cyclooxygenase-2 in hematopoietic cells results in salt-sensitive hypertension.
Zhang MZ, Yao B, Wang Y, Yang S, Wang S, Fan X, Harris RC
The Journal of clinical investigation 2015 Nov 2;125(11):4281-94
The Journal of clinical investigation 2015 Nov 2;125(11):4281-94
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U
Nature 2015 Apr 30;520(7549):692-6
Nature 2015 Apr 30;520(7549):692-6
The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
Rajnai H, Heyning FH, Koens L, Sebestyén A, Andrikovics H, Hogendoorn PC, Matolcsy A, Szepesi Á
Virchows Archiv : an international journal of pathology 2014 Feb;464(2):229-39
Virchows Archiv : an international journal of pathology 2014 Feb;464(2):229-39
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
Grant BW, Jung SH, Johnson JL, Kostakoglu L, Hsi E, Byrd JC, Jones J, Leonard JP, Martin SE, Cheson BD
Cancer 2013 Nov 1;119(21):3797-804
Cancer 2013 Nov 1;119(21):3797-804
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- FACS